MED vs TRIP

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 13, 2026. You may want to consider a long position or call options on MED as a result. In 58 of 95 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 61%.

The Moving Average Convergence Divergence (MACD) for MED just turned positive on October 14, 2026. Looking at past instances where MED's MACD turned positive, the stock continued to rise in 40 of 58 cases over the following month. The odds of a continued upward trend are 69%.

MED moved above its 50-day moving average on October 26, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for MED crossed bullishly above the 50-day moving average on October 22, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 56%.

Following a +5.03% 3-day Advance, the price is estimated to grow further. Considering data from situations where MED advanced for three days, in 146 of 239 cases, the price rose further within the following month. The odds of a continued upward trend are 61%.

Bearish Trend Analysis

The 10-day RSI Indicator for MED moved out of overbought territory on November 10, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 14 similar instances where the indicator moved out of overbought territory. In 12 of the 14 cases, the stock moved lower in the following days. This puts the odds of a move lower at 86%.

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where MED declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.

MED broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 3 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.729) is normal, around the industry mean (8.051). MED has a moderately low P/E Ratio (-5.498) as compared to the industry average of (10.423). Projected Growth (PEG Ratio) (0.230) is also within normal values, averaging (4.440). MED's Dividend Yield (0.515) is considerably higher than the industry average of (0.081). P/S Ratio (0.416) is also within normal values, averaging (1.645).

The Tickeron Price Growth Rating for this company is 43 (best 1 - 100 worst), indicating steady price growth. MED’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MED’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 85, placing this stock worse than average.

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

Following a +7.44% 3-day Advance, the price is estimated to grow further. Considering data from situations where TRIP advanced for three days, in 196 of 271 cases, the price rose further within the following month. The odds of a continued upward trend are 72%.

TRIP may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 116 of 161 cases where TRIP Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 72%.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TRIP as a result. In 66 of 80 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 82%.

The Moving Average Convergence Divergence Histogram (MACD) for TRIP turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 33 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 79%.

TRIP moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for TRIP crossed bearishly below the 50-day moving average on November 06, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 67%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where TRIP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 3 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 51 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.238) is normal, around the industry mean (-0.351). TRIP's P/E Ratio (127.182) is considerably higher than the industry average of (24.800). Projected Growth (PEG Ratio) (0.431) is also within normal values, averaging (1.617). TRIP's Dividend Yield (2.000) is considerably higher than the industry average of (0.224). TRIP's P/S Ratio (0.585) is slightly lower than the industry average of (2.754).

The Tickeron Price Growth Rating for this company is 81 (best 1 - 100 worst), indicating slightly worse than average price growth. TRIP’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 90 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TRIP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 75, placing this stock worse than average.